<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85827">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02115750</url>
  </required_header>
  <id_info>
    <org_study_id>CHS-0214-02</org_study_id>
    <nct_id>NCT02115750</nct_id>
  </id_info>
  <brief_title>Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)</brief_title>
  <acronym>CHS-0214-02</acronym>
  <official_title>A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Rheumatoid Arthritis and Inadequate Response to Treatment With Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coherus Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Coherus Biosciences, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two part study comparing CHS-0214 to Enbrel in patients with active rheumatoid
      arthritis and an inadequate response with Methotrexate (MTX) who are naive to biologic
      therapies.

      Pt.1 is a 24-week randomized, double-blind, active-control, parallel-group, multi-center
      global study. The primary end point is 20% improvement in American College of Rheumatology
      criteria (ACR-20) at week 24. Comparing CHS-0214 to Enbrel for efficacy and safety.

      Pt. 2 is an open-label single arm study in which patients with at least an ACR-20 response
      receive CHS-0214. Continued response and safety will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>ACR-20</measure>
    <time_frame>24-weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">486</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Enbrel (etanercept)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enbrel 50mg weekly times 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHS-0214</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHS-0214 50mg weekly times 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>Head-to-head comparison</description>
    <arm_group_label>Enbrel (etanercept)</arm_group_label>
    <other_name>Enbrel</other_name>
    <other_name>European Enbrel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CHS-0214</intervention_name>
    <arm_group_label>CHS-0214</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female adults

          -  RA diagnosis for 6 months

          -  On stable dose of MTX of 8mg to 25mg per week

          -  Active disease: greater than 6 tender joints, greater than 6 swollen joints,
             C-reactive protein (CRP) greater than or equal to 0.5mg/dL, and disease activity
             score (DAS) with 28 joints (DAS28-CRP(4)) greater than or equal to 3.2

        Exclusion Criteria:

          -  Use of prednisone greater than 10mg/day

          -  Use of greater than one non-steroidal anti-inflammatory drug (NSAID)

          -  Use of biologic therapies for any cause

          -  Chemistry and hematology values outside protocol specified range

          -  Positive QuantiFERON-tuberculosis (TB) Gold Test

          -  Evidence of active lung disease on chest x-ray

          -  Major systemic infections

          -  Presence of significant comorbid conditions

          -  Known allergy to latex

          -  Women who are pregnant or nursing
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara K Finck, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Coherus Biosciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Metroplex Clinical Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tonja Hill</last_name>
      <phone>214-424-0416</phone>
      <email>thill@mcrcdallas.com</email>
    </contact>
    <investigator>
      <last_name>Stanley Cohen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>May 12, 2014</lastchanged_date>
  <firstreceived_date>April 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CHS-0214</keyword>
  <keyword>Enbrel</keyword>
  <keyword>RA</keyword>
  <keyword>Biosimilar</keyword>
  <keyword>Etanercept</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>TNFR-Fc fusion protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
